GeneType Unveils Cutting-Edge Precision Oncology Tests

GeneType (ASX: GTG), a leader in genomic testing, has launched a precision oncology division to enhance cancer treatment with a new series of diagnostic tests under its geneType brand. These tests, developed in collaboration with the University of Melbourne, aim to determine the most effective therapies for various cancers, including melanoma and lung cancer.

The tests will analyze methylation patterns, solid tumor mutations, and use liquid biopsies for disease monitoring. This innovation is expected to significantly improve early detection and treatment outcomes, making these advanced genomic tests accessible through a guideline-driven reimbursement approach. With the global genomics market growing rapidly, these tests are poised to capture a substantial market opportunity, enhancing patient care and reducing healthcare costs.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com